VI

VIVOZON PHARMACEUTICAL CO., LTD.

Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.

082800 | KO

Overview

Corporate Details

ISIN(s):
KR7082800004
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약공단2길 34-40, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vivozon Pharmaceutical Co., Ltd. is a global drug development company established in 2008, focused on creating innovative treatments for pain and central nervous system (CNS) diseases. The company's core research centers on a multi-target drug discovery platform designed to develop chemical drugs with synergistic efficacy. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic. Vivozon utilizes an efficacy-based screening system from the early stages of discovery to advance its pipeline, which also targets conditions such as depression, substance use disorders, and neurodegenerative diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-07-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.1 KB
2025-07-14 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-06-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 121.1 KB
2025-06-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-22 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 54.9 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.4 MB
2025-04-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 111.3 KB
2025-04-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-04-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 108.4 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 17.7 KB
2025-03-27 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-03-24 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.7 KB
2025-03-21 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.8 KB

Automate Your Workflow. Get a real-time feed of all VIVOZON PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for VIVOZON PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for VIVOZON PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea
229000
GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.